Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.
We have reported that [methyl- (11)C] (3 R,5 R)-5-(3-methoxyphenyl)-3-[(R)-1-phenylethylamino]-1-(4-trifluoromethylphenyl)pyrrolidin-2-one ([(11)C] 8, [(11)C]MePPEP) binds with high selectivity to cannabinoid type-1 (CB 1) receptors in monkey brain in vivo. We now describe the synthesis of 8 and four analogues, namely, the 4-fluorophenyl (16, FMePPEP), 3-fluoromethoxy (20, FMPEP), 3-fluoromethoxy- d 2 (21, FMPEP- d 2), and 3-fluoroethoxy analogues (22, FEPEP), and report their activity in an ex vivo model designed to identify compounds suitable for use as positron emission tomography (PET) ligands. These ligands exhibited high, selective potency at CB 1 receptors in vitro (K b < 1 nM). Each ligand (30 microg/kg, iv) was injected into rats under baseline and pretreatment conditions (3, rimonabant, 10 mg/kg, iv) and quantified at later times in frontal cortex ex vivo with liquid chromatography-mass spectrometry (LC-MS) detection. Maximal ligand uptakes were high (22.6-48.0 ng/g). Under pretreatment, maximal brain uptakes were greatly reduced (6.5-17.3 ng/g). Since each ligand readily entered brain and bound with high selectivity to CB 1 receptors, we then established and here describe methods for producing [(11)C] 8, [(11)C] 16, and [(18)F] 20- 22 in adequate activities for evaluation as candidate PET radioligands in vivo.
Donohue
Sean R
SR
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA.
Krushinski
Joseph H
JH
Pike
Victor W
VW
Chernet
Eyassu
E
Phebus
Lee
L
Chesterfield
Amy K
AK
Felder
Christian C
CC
Halldin
Christer
C
Schaus
John M
JM
D000818:Animals; D002853:Chromatography, Liquid; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D049268:Positron-Emission Tomography; D011760:Pyrrolidinones / Q000138:chemical synthesis* / Q000378:metabolism* / Q000494:pharmacology; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism*; D021241:Spectrometry, Mass, Electrospray Ionization
D008024:Ligands; D011760:Pyrrolidinones; D043884:Receptor, Cannabinoid, CB1
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
2308954
Mol Imaging Biol. 2004 Nov-Dec;6(6):373-84
15564148
FEBS Lett. 2005 Jan 3;579(1):259-64
15620723
Appl Radiat Isot. 2002 Sep;57(3):347-52
12201141
Nature. 1993 Sep 2;365(6441):61-5
7689702
J Med Chem. 2005 Aug 11;48(16):5059-87
16078824
J Neurosci. 1991 Feb;11(2):563-83
1992016
J Nucl Med. 2006 Oct;47(10):1689-96
17015906
Annu Rev Pharmacol Toxicol. 2006;46:101-22
16402900
Mol Pharmacol. 1988 Nov;34(5):605-13
2848184
Annu Rev Pharmacol Toxicol. 2001;41:443-70
11264465
FEBS Lett. 1994 Aug 22;350(2-3):240-4
8070571
Synapse. 2004 Aug;53(2):57-67
15170818
Eur J Pharmacol. 1997 Nov 19;339(1):53-61
9450616
Nucl Med Biol. 2000 Aug;27(6):529-32
11056365
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9800-5
17535893
Science. 2005 Oct 14;310(5746):329-32
16224028
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
4202581
Brain Res. 2006 Feb 3;1071(1):10-23
16472786
Life Sci. 2005 Dec 12;78(4):340-6
16139310
Neuropsychopharmacology. 2008 Jan;33(2):259-69
17392732
Mol Imaging Biol. 2003 Nov-Dec;5(6):363-75
14667491
J Biol Chem. 1995 Feb 24;270(8):3726-31
7876112
Appl Radiat Isot. 2001 Jun;54(6):927-33
11300406
Mol Imaging Biol. 2003 Nov-Dec;5(6):376-89
14667492
J Med Chem. 2007 Jul 26;50(15):3427-30
17608398
Nature. 1990 Aug 9;346(6284):561-4
2165569
Life Sci. 2006 May 22;78(26):3007-12
16434058
J Psychopharmacol. 1993 Jan;7(2):139-58
22290661
Tetrahedron Lett. 1967 Mar;12:1109-11
6039537
J Pharmacol Exp Ther. 1999 May;289(2):946-55
10215674
Appl Radiat Isot. 2002 Sep;57(3):335-42
12201139
J Pharmacol Exp Ther. 1994 Mar;268(3):1612-23
8138973
Pharmacol Rev. 2002 Jun;54(2):161-202
12037135